Clinical Trial Update: CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating CP-868,596 alone and in combination with AG-013736 and docetaxel in patients with solid tumors has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• AG-013736
• CP-868,596 (CP-868,596)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Arog Pharmaceuticals, Inc. | Conditions: Advanced Solid Tumors | Phase 1 | Status: COMPLETED